Comparison between Accretion Pharmaceuticals IPO and Safecure IPO.
Accretion Pharmaceuticals IPO is a SME Fixed Price IPO proposed to list at NSE SME while Safecure IPO is a SME Fixed Price proposed to list at BSE SME.
| Accretion Pharmaceuticals IPO | Safecure IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Jawa Capital Services Pvt.Ltd. | Sun Capital Advisory Services Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Gretex Share Broking Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Accretion Pharmaceuticals IPO is up to ₹28.26 Cr whereas the issue size of the Safecure IPO is up to ₹0.00 Cr. The final issue price of Accretion Pharmaceuticals IPO is ₹101.00 per share and of Safecure IPO is .
| Accretion Pharmaceuticals IPO | Safecure IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹96.00 per share | |
| Issue Price (Upper) | ₹101.00 per share | |
| Issue Price (Final) | ₹101.00 per share | |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 27,98,400 shares | 30,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹28.26 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 27,98,400 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹28.26 Cr | up to ₹0.00 Cr |
Accretion Pharmaceuticals IPO opens on May 14, 2025, while Safecure IPO opens on . The closing date of Accretion Pharmaceuticals IPO and Safecure IPO is May 16, 2025, and , respectively.
| Accretion Pharmaceuticals IPO | Safecure IPO | |
|---|---|---|
| Anchor Bid Date | May 13, 2025 | |
| Issue Open | May 14, 2025 | |
| Issue Close | May 16, 2025 | |
| Basis Of Allotment (Tentative) | May 19, 2025 | |
| Initiation of Refunds (Tentative) | May 20, 2025 | |
| Credit of Share (Tentative) | May 20, 2025 | |
| Listing date (Tentative) | May 21, 2025 | |
| Anchor Lockin End date 1 | Jun 18, 2025 | |
| Anchor Lockin End date 2 | Aug 17, 2025 |
Accretion Pharmaceuticals IPO P/E ratio is 21.29, as compared to Safecure IPO P/E ratio of .
| Accretion Pharmaceuticals IPO | Safecure IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Accretion Pharmaceuticals Limited Financial Information (Restated Consolidated)
| Safecure Services Limited Financial Information (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100.00 | 94.33 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 21.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹112.27 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 72.47% | 37.82% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 36.73% | 28.31% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.52 | 0.95 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 72.47% | 37.82% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Accretion Pharmaceuticals IPO Retail Individual Investors (RII) are offered 12,22,800 shares while in Safecure IPO retail investors are offered 12,22,800 shares. Qualified Institutional Buyers (QIB) are offered 1,41,600 shares in Accretion Pharmaceuticals IPO and in Safecure IPO.
| Accretion Pharmaceuticals IPO | Safecure IPO | |
|---|---|---|
| Anchor Investor Reserveration | 2,11,200 shares | |
| Market Maker Reserveration | 1,47,600 shares | |
| QIB | 1,41,600 shares | |
| NII | 12,22,800 shares | |
| RII | 12,22,800 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 27,98,400 shares |
Accretion Pharmaceuticals IPO subscribed 7.67x in total, whereas Safecure IPO subscribed .
| Accretion Pharmaceuticals IPO | Safecure IPO | |
|---|---|---|
| QIB (times) | 12.14x | |
| NII (times) | 4.28x | |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 10.54x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 7.67x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
